S

SpringWorks Therapeutics

Clinical-stage precision medicines for cancer

Territory Business Manager

Full-TimePosted on 10/19/2026
$185k - $210k
Senior
Bachelor's
Seattle, WA, USA
RemoteRemote role; candidate must live within the identified territory. Domestic travel may be required up to 50%.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 7 years of pharmaceutical and/or biotech experience is required.
  • At least 5 years of proven rare disease sales experience in the pharmaceutical or healthcare industry, with demonstrated successful results, is required.
  • Neurology experience with both pediatric and adult populations is required.
  • Oncology experience is required.
  • Experience selling in a competitive market is required.
  • Experience in rare disease sales is required.
  • Experience with virtual selling and a track record of embracing technology are required.
  • Strong expertise in reimbursement and managed care knowledge is required.
  • A valid and active driver's license is required.
  • The candidate must live within the identified territory.
  • The position may require domestic travel up to 50% of the time.
Responsibilities
  • Lead sales at the territory level and serve as the primary liaison between customers and SpringWorks Therapeutics.
  • Deliver on revenue goals by executing brand objectives through communication of approved clinical information, rigorous account planning, and commercial team collaboration.
  • Appropriately promote rare disease products and implement programs and initiatives in accordance with company and industry guidelines.
  • Maintain expert operating knowledge of company policies and guidelines, including those addressing interactions with healthcare professionals, compliance, and business conduct.
  • Ensure compliance with company, industry, and government laws and regulations, including guidelines pertaining to ethical business practices.
  • Be accountable for overall territory revenue and customer support.
  • Achieve short- and long-term sales objectives by identifying customer needs and providing solutions to create professional relationships with customers in live and virtual settings and within community and academic settings.
  • Build relationships with key healthcare professionals, physician practices, hospitals and clinics, and practice managers across treatment and academic settings, including major cancer centers.
  • Develop deep market, customer, product, and competitive insights as a territory expert; understand changes in the healthcare landscape and strategically adapt.
  • Complete ongoing training and development in product knowledge, selling skills, goal setting, planning and analysis, marketing tools, clinical information, and sales competencies.
  • Identify and enact appropriate ways to put patients and customers first, prioritizing tasks that enable faster delivery of medicines to patients.
  • Review data, understand trends, prepare and communicate applicable plans, and adopt digital platforms and omnichannel strategies.
  • Participate fully in field coaching sessions, including receiving guidance, positive reinforcement, and corrective action where needed, focusing on account-plan execution and competency development to meet revenue targets.
  • Collaborate and maintain ongoing communication and tactical coordination with field and headquarters colleagues.
  • Support local and area key opinion leaders.
Desired Qualifications
  • An advanced degree is preferred.
  • An in-depth understanding of the neurology and oncology landscape and market dynamics is highly desirable.

About the company

S

SpringWorks Therapeutics

View

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines for patients with rare diseases and cancer. Its approach is to tailor therapies based on the genetic and molecular profile of a disease, aiming to improve treatment effectiveness and safety for underserved patient groups. The company advances drug candidates through clinical trials (such as Phase 1b and 2) and pursues partnerships with other pharmaceutical companies to acquire, develop, and commercialize therapies. Unlike broader, non-targeted programs, SpringWorks focuses on niche patient populations defined by genetic profiles and collaborates on development and commercialization, broadening access to targeted treatments. The company’s goal is to bring targeted therapies to market that address unmet medical needs in oncology and rare diseases, improving outcomes for patients with specific genetic conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2017

Get referred to SpringWorks Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck closed the $3.4 billion deal in July 2025, validating SpringWorks' assets.
  • Ogsiveo and Gomekli now generate commercial revenue from specialist rare-tumor markets.
  • EMA review of mirdametinib still opens a large ex-U.S. expansion path.

What critics are saying

  • SpringWorks no longer exists as an independent public company after Merck's acquisition.
  • Integration into Merck can cut SpringWorks hiring autonomy and reshape Connecticut operations quickly.
  • Commercial dependence on two rare-tumor drugs leaves Merck exposed if launches disappoint.

What makes SpringWorks Therapeutics unique

  • SpringWorks built two FDA-approved rare-tumor drugs before Merck's 2025 acquisition.
  • Its precision-medicine pipeline targets genetically defined diseases, not broad oncology franchises.
  • Gomekli gained U.S. pediatric approval and keeps EU expansion optionality alive.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Paid Vacation
  • Paid Sick Leave
  • Professional Development Budget
  • Flexible Work Hours
  • Remote Work Options

Growth & Insights and Company News

6 month growth

2%

1 year growth

4%

2 year growth

7%
Merck Group
Sep 20th, 2026
SpringWorks-acquisiton-completed

We have closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion).

AD HOC NEWS
May 21st, 2026
SpringWorks Therapeutics agrees to cash merger with $3.52B market cap desmoid tumor franchise

SpringWorks Therapeutics has completed a cash merger, according to a Robinhood corporate actions update from May 2026. The Nasdaq-listed biotech, which traded at $46.99 with a market capitalisation of approximately $3.52 billion as of mid-May, focuses on developing targeted therapies for rare diseases and oncology. The company's lead asset is nirogacestat, a gamma-secretase inhibitor for desmoid tumours, addressing significant unmet medical needs in this rare soft-tissue condition. SpringWorks also develops mirdametinib, a MEK inhibitor targeting neurofibromatosis type 1 plexiform neurofibromas. As a clinical-stage company, SpringWorks currently reports negative earnings, reflecting ongoing development costs typical of pre-commercial biotechnology firms. The company operates within the US-centred biotech ecosystem, with most clinical trials and regulatory interactions based in the United States.

AllSci
Mar 17th, 2026
R1 Therapeutics launches with oversubscribed USD 77.5m Series A.

R1 Therapeutics launches with oversubscribed USD 77.5m Series A. March 17, 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A financing totaling USD 77.5 million. The company is focused on developing therapies for chronic kidney disease, the lead program targeting hyperphosphatemia in dialysis patients. R1 acquired exclusive global rights outside of Greater China to that program - AP306, a pan phosphate transporter inhibitor - via a license deal with China-based Alebund Pharmaceuticals announced alongside the Series A. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and US Renal Care. The company said proceeds will fund a global development program for AP306, including a Phase IIb study planned to begin later this year. This is R1 Therapeutics' first disclosed funding round, coinciding with the company's formal launch. AP306, previously known as EOS789, was originally discovered by Chugai Pharmaceutical Co. and subsequently licensed to Alebund Pharmaceuticals, which conducted a Phase IIa study in hemodialysis patients in China. Results from that trial, published in Kidney International Reports, showed statistically significant reductions in serum phosphate with a tolerable safety profile. AP306 is described as the only clinical-stage agent that blocks active phosphate transport via three GI-tract transporters - NaPi-2b, PiT-1, and PiT-2 - distinguishing it from phosphate binders, which inhibit passive transport and have been the standard of care for six decades. More than 40% of US dialysis patients fail to reach phosphate targets with existing therapies, which carry high pill burden and GI tolerability issues, the company said. R1 is led by co-founder, president, and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of biopharmaceutical experience. Co-founder L. Mary Smith, Ph.D., who previously served as chief development officer at SpringWorks Therapeutics, joins as chief operating officer. Your email address will not be published. Required fields are marked *

PharmiWeb
May 27th, 2025
Springworks Therapeutics Receives Positive Chmp Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With Nf1-Pn

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN. – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –. – Decision from European Commission expected in the third quarter of 2025 –

Merck Group
May 5th, 2025
agreement-to-acquire-springworks

Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.